Aletta Falk

Director Medical Affairs Haemophilia
Sobi, Stockholm, Sweden

Presentation(s):

• PB1153 - Interim Analysis from B-MORE, a 24-month Prospective, Multicentre, Non-interventional Study on Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM